Genmab A/S
General ticker "GNMSF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $17.0B (TTM average)
Genmab A/S does not follow the US Stock Market performance with the rate: -6.0%.
Estimated limits based on current volatility of 0.3%: low 337.06$, high 338.87$
Factors to consider:
- Total employees count: 548 as of 2019
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [208.22$, 339.76$]
- 2026-12-31 to 2027-12-31 estimated range: [185.03$, 307.90$]
Short-term GNMSF quotes
Long-term GNMSF plot with estimates
Financial data
| YTD | 2025-12-31 |
|---|---|
| Operating Revenue | $3,851.06MM |
| Operating Expenses | $2,557.02MM |
| Operating Income | $1,294.04MM |
| Non-Operating Income | $-47.62MM |
| Interest Expense | $63.15MM |
| R&D Expense | $1,613.92MM |
| Income(Loss) | $1,246.42MM |
| Taxes | $249.49MM |
| Net Income(Loss)* | $996.93MM |
| Stockholders Equity | $5,821.05MM |
| Inventory | $17.92MM |
| Assets | $12,815.86MM |
| Operating Cash Flow | $1,227.78MM |
| Capital expenditure | $38.30MM |
| Investing Cash Flow | $-5,841.81MM |
| Financing Cash Flow | $4,957.72MM |
| Earnings Per Share** | $16.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.